

Ref: STEX/INTIMATION/2026-27

Date: August 07, 2026

BSE Limited

Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

Subject: Intimation under SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited ("the Company") is scheduled to be held on Friday, August 14, 2026, at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi – 110019, inter alia, to consider and approve the following businesses:

1. To consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026;
2. To consider and approve the Draft Annual Report of the Company for the financial year 2025-26;
3. To consider and approve the Draft Cost Audit Report of the Company for the financial year 2025-26; and
4. To transact any other business with the permission of the Chair.

It was informed that pursuant to the Company's Code of Conduct framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and amendments made there under, the trading window for dealing in the shares of the Company is closed for all designated persons of the Company from the July 01, 2026 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.

This is for your information and record.

Yours faithfully

For Medicamen Biotech Limited

Parul Choudhary

Company Secretary & Compliance Officer

ACS: 44157